6 results about "Amphipathic helix" patented technology

The invention discloses an antibacterial peptide and application thereof in preventing and treating dental plaque and gingival problems, and belongs to the technical field of biology. According to the invention, two cationic antibacterial peptides LR18 and LR18-2 with amphiphilic alpha-helical structures are designed from the beginning. The two antibacterial peptides have good antibacterial and bactericidal activity on oral periodontal pathogenic bacteria (including fusobacterium nucleatum, porphyromonas gingivalis and streptococcus mutans), the minimum inhibitory concentration (MIC) is 62.5-500 [mu] g / mL, and the minimum bactericidal concentration (MBC) is 62.5-2000 [mu] g / mL. The structure is simple, the chemical synthesis difficulty is low, a high-purity product can be directly synthesized, the cell hemolytic activity is low, the safety is high, the product can be used for preparing oral antibacterial drugs and / or oral care products, and oral diseases are prevented and treated by inhibiting the growth of oral periodontal pathogenic bacteria.

The present disclosure describes a peptide scaffold for producing vaccines. The peptide scaffold includes a peptide that self-assembles into a hapten carrier (hC) includes amphipathic alpha-helices. The peptide includes heptad repeats following a specific pattern. The hC further includes hapten or an agent conjugated to it, and optionally the hC includes one or more T-cell epitopes at the N- and / or C-terminus of the one or more amphipathic alpha-helices. The present disclosure also describes compositions including immunogenic compositions including the hapten-hC or agent-hC conjugate.

The cryo-electron microscope sample preparation kit contains an amphipathic protein and a protein crosslinking agent, or an expression vector containing a nucleic acid sequence encoding the amphipathic protein. The kit also includes an ice thickness control molecule to which an amphipathic protein is attached. The amphipathic protein may have an amphipathic α-helix structure and may be either an antifreeze protein or a type I antifreeze protein.

The invention discloses an alpha-spiral antibacterial peptide containing beta-amino acid and application thereof, the antibacterial peptide is obtained by taking an amphiphilic alpha-spiral structure containing glycine (G) and threonine (T) as a basic framework and introducing different numbers of beta-amino acid, the sequence general formula of the antibacterial peptide is GXXYYYYTXX-NH2, X = Leu, beta-Leu, beta-Leu, beta-Leu, beta-Leu, beta-Leu, beta-Leu, beta-Leu, beta-Leu, beta-Leu, beta-Leu, beta-Leu, beta-Leu, beta-Leu, beta-Leu, beta Y is equal to Lys, Arg, Ile, beta-Lys, beta-Arg and beta-Ile. Experimental results show that the novel antibacterial peptide containing the beta-amino acid has relatively strong antibacterial activity on gram negative bacteria, and has relatively high stability and safety. In addition, the antibacterial peptide is not easy to induce bacteria to generate drug resistance, and can inhibit the development of antibiotic-induced bacterial drug resistance. Therefore, the novel antibacterial peptide containing the beta-amino acid has a good application prospect in the aspect of development of antibacterial drugs.

The present disclosure describes a GnRH therapeutic for neutralizing GnRH levels in subjects which can reduce testosterone levels to attenuate or eliminate prostate cancer cell growth and / or metastasis. The therapeutic is produced synthetically. The GnRH therapeutic includes a hapten carrier (hC) comprising a monomeric peptide (MP), synthesized separately from the GnRH peptide, and following self-assembly of the hC, GnRH is covalently coupled to form a GnRH-hC conjugate which can serve as a therapeutic. The MP includes heptad repeats following a specific pattern. The hC can include a GnRH peptide attached to a monomeric peptide prior to self-assembly to form a therapeutic. Optionally, the GnRH-hC conjugate further includes one or more T-cell epitopes at the N- and / or C-terminus of the one or more amphipathic alpha-helices. The present disclosure also describes compositions including immunogenic compositions including the therapeutics described herein.

The present disclosure describes a unique viral peptide (VP) vaccine for preventing or treating viral diseases. The vaccine is produced synthetically and includes no production steps in biological cells (e.g. E. coli, CHO cells, yeast cells) that would require subsequent endotoxin assays / removal or viral clearance procedures. The hC peptide is synthesized separately from the VP, and following self-assembly of the hC, the VP is covalently coupled to form the VP-hC conjugate which can serve as a vaccine for preventing or treating viral diseases. The hC includes heptad repeats following a specific pattern. Optionally, the VP-hC conjugate further includes one or more T-cell epitopes at the N- and / or C-terminus of the one or more amphipathic alpha-helices. The present disclosure also describes compositions comprising immunogenic compositions including VP-hC conjugate.